Paper Details

  1. Home
  2. Paper Details

Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial.

Author: , BockC T, BrosteanuO, FiedlerG M, FrankeA, MannsM P, RufB, RömmeleU, RößlerS, SpenglerU, TeuberG, ThieryJ, TillmannH L, TrautweinC, WedemeyerH, WiegandJ, WächtlerM, ZeuzemS

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lamivudine treatment was studied in patients with severe acute hepatitis B infection. While the study did not find statistically significant differences between treatment groups due to limited patient numbers, lamivudine may improve recovery time and prevent progression to liver failure.
Paper Details　
Original Abstract of the Article :
Acute hepatitis B virus (aHBV) infection can lead to fulminant liver failure, which likely is prevented by early lamivudine therapy. Even nonfulminant but severe acute hepatitis B can lead to significant morbidity and impaired quality of life. Therefore, lamivudine was evaluated in patients with sev...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/jvh.12210

データ提供：米国国立医学図書館（NLM）

Treatment of severe, nonfulminant acute hepatitis B

This research delves into the complex world of hepatitis B, a serious liver infection. Imagine a desert oasis, where the delicate balance of life is easily disrupted. Similarly, the liver is a vital organ, and disruption of its function can have devastating consequences. The study investigates the potential of lamivudine, an antiviral medication, to treat severe cases of acute hepatitis B. The study focused on patients with severe acute hepatitis B infection and their response to lamivudine treatment.

A Promising Treatment

While the study did not reach statistically significant results due to a smaller than expected patient number, it suggests that lamivudine may be effective in ameliorating severe acute hepatitis B infection. The findings indicate that lamivudine may help patients recover faster, potentially reducing the severity and duration of the infection. This study offers valuable insights into the potential of lamivudine as a treatment option for severe acute hepatitis B.

Protecting Your Liver

Hepatitis B is a serious condition that can lead to significant liver damage. It's important to get vaccinated against hepatitis B to protect yourself and your loved ones. Additionally, practicing safe sex and avoiding contact with infected blood can help reduce the risk of infection. If you're concerned about your risk of hepatitis B, consult with a healthcare professional.

Dr. Camel's Conclusion

This study highlights the ongoing struggle against hepatitis B, a disease that can be as unpredictable as a desert sandstorm. The research provides valuable insights into the potential of antiviral medications like lamivudine to help manage this serious condition. While the study did not reach conclusive results due to limited patient numbers, it offers a glimpse of hope for a future where we can more effectively treat and prevent hepatitis B infection. As we continue to explore the vast desert of medical knowledge, we must remain persistent in our quest for better treatments and preventive measures against this debilitating disease.

Date :
  1. Date Completed 2015-10-12
  2. Date Revised 2014-10-01
Further Info :

Pubmed ID

24329913

DOI: Digital Object Identifier

10.1111/jvh.12210

Related Literature

Article Analysis
・Side Effects of telbivudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.